Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?
The mean of analysts' price targets for Profound Medical (PROF) points to a 58.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Profound Medical Q2 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of TULSA product shipments completed in July rather than June.
Profound Medical (PROF) Q2 Earnings Surpass Estimates
Profound Medical (PROF) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.52 per share a year ago.
Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Profound Medical Q1 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supported by new clinical data, payer progress and a growing installed base.
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.36 per share a year ago.
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Profound Medical (PROF) Soars 9.5%: Is Further Upside Left in the Stock?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
